Cameil Wilson-Clarke

Dr. Cameil Wilson-Clarke

University of the West Indies, Mona, Jamaica
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
DMDonovan Anthony McGrowder
Donovan Anthony McGrowder
FMFabian G. Miller
Fabian G. Miller
KVKurt Vaz
Kurt Vaz
CNChukwuemeka Nwokocha
Chukwuemeka Nwokocha
CWCameil Wilson-Clarke
Cameil Wilson-Clarke
RARuby Alexander-Lindo
Ruby Alexander-Lindo
Alzheimer’s disease is a progressive, clinically heterogeneous, and particularly complex neurodegenerative disease characterized by a decline in cognition. Over the last two decades, there has been significant growth in the investigation of cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease. This review presents current evidence from many clinical neurochemical studies, with findings that attest to the efficacy of existing core CSF biomarkers such as total tau, phosphorylated tau, and amyloid-β (Aβ42), which diagnose Alzheimer’s disease in the early and dementia stages of the disorder. The heterogeneity of the pathophysiology of the late-onset disease warrants the growth of the Alzheimer’s disease CSF biomarker toolbox; more biomarkers showing other aspects of the disease mechanism are needed. This review focuses on new biomarkers that track Alzheimer’s disease pathology, such as those that assess neuronal injury (VILIP-1 and neurofilament light), neuroinflammation (sTREM2, YKL-40, osteopontin, GFAP, progranulin, and MCP-1), synaptic dysfunction (SNAP-25 and GAP-43), vascular dysregulation (hFABP), as well as CSF α-synuclein levels and TDP-43 pathology. Some of these biomarkers are promising candidates as they are specific and predict future rates of cognitive decline. Findings from the combinations of subclasses of new Alzheimer’s disease biomarkers that improve their diagnostic efficacy in detecting associated pathological changes are also presented.

14 August 2020 in Medicines
Verified
Journal Article
Open access
PDF file
DMDonovan Anthony McGrowder
Donovan Anthony McGrowder
FMFabian G. Miller
Fabian G. Miller
CNChukwuemeka Nwokocha
Chukwuemeka Nwokocha
MAMelisa S. Anderson
Melisa S. Anderson
CWCameil Wilson-Clarke
Cameil Wilson-Clarke
JBJabari Brown
Jabari Brown
Background: Breast cancer is one of the principal causes of death among women and there is a pressing need to develop novel and effective anti-cancer agents. Natural plant products have shown promising results as anti-cancer agents. Their effectiveness is reported as decreased toxicity in usage, along with safety and less recurrent resistances compared with hormonal targeting anti-cancer agents. Methods: A literature search was conducted for all English-language literature published prior to June 2020. The search was conducted using electronic databases, including PubMed, Embase, Web of Science, and Cochrane Library. The search strategy included keywords such as breast cancer, herbs, anti-cancer biologically active components, clinical research, chemotherapy drugs amongst others. Results: The literature provides documented evidence of the chemo-preventative and chemotherapeutic properties of Ginseng, garlic (Allium sativum), Black cohosh (Actaea racemose), Tumeric (Curcuma longa), Camellia sinenis (green tea), Echinacea, Arctium (burdock), Flaxseed (Linum usitatissimum) and Black Cumin (Nigella sativa). Conclusions: The nine herbs displayed anti-cancer properties and their outcomes and mechanisms of action include inhibition of cell proliferation, angiogenesis and apoptosis as well as modulation of key intracellular pathways. However, more clinical trials and cohort human studies should be conducted to provide key evidence of their medical benefits.

18 December 2024 in Parasitology Research
Verified
Journal Article
Closed access
PDF file
NKNadia K. Khouri
Nadia K. Khouri
SSSatish Singh
Satish Singh
SNSimmoy A. A. Noble
Simmoy A. A. Noble
TKTiffany V. Kirlew
Tiffany V. Kirlew
MGMario A. J. Golding
Mario A. J. Golding
SSSimone Sandiford
Simone Sandiford

31 December 2018 in Pharmacy Practice
Verified
Journal Article
Open access
PDF file
JMJodi-Ann McKenzie
Jodi-Ann McKenzie
CWCameil Wilson-Clarke
Cameil Wilson-Clarke
JPJennifer Prout
Jennifer Prout
JCJacqueline Campbell
Jacqueline Campbell
RDRhea-Danielle Douglas
Rhea-Danielle Douglas
Maxine Gossell-WilliamsMaxine Gossell-Williams
Maxine Gossell-Williams
Pharmacy Practice is a free full-text journal with a scope on the practice of pharmacy. Pharmacy Practice covers pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology

8 September 2021
Verified
Book Chapter
Open access
PDF file
DMDonovan McGrowder
Donovan McGrowder
FMFabian G. Miller
Fabian G. Miller
CNChukwuemeka Nwokocha
Chukwuemeka Nwokocha
CWCameil Wilson-Clarke
Cameil Wilson-Clarke
MAMelisa Anderson
Melisa Anderson
LWLowen Williams
Lowen Williams
Breast cancer remains one of the most frequent cancers affecting women globally. The incidence of breast cancer is rising due to improved screening and awareness, and there is epidemiological data signifying an interaction among environmental and biological risk factors in the development and progress of breast cancer. There is substantial experimental data of the protective effect of micronutrient antioxidants for breast cancer via alteration of many signaling pathways and molecular events including inducing apoptosis, and inhibition of breast cancer cell proliferation and invasion. The main focus of this review is to examine past and current epidemiological evidence that suggests that nutritional micronutrients with antioxidant properties in dietary or supplemental form may be beneficial in protecting women against breast cancer and affect outcomes.

Verified
Journal Article
Open access
PDF file
MBMichelle Georgiana Brown
Michelle Georgiana Brown
JLJohn Lindo
John Lindo
IVIvan Vickers
Ivan Vickers
KNKereann Nelson
Kereann Nelson
YPYakima Phillips
Yakima Phillips
ATAndrew Henry Talal
Andrew Henry Talal
Hepatitis C (HCV) continues to present a global public health challenge, with no vaccine available for prevention. Despite the availability of direct-acting antivirals (DAAs) to cure HCV, it remains prevalent in many regions including the Caribbean. As efforts are made to eliminate HCV from the region, existing barriers, such as the high cost of DAAs and lack of an established database of HCV cases within the Caribbean, must be addressed. This review seeks to assess epidemiologic trends (seroprevalence and genotypic diversity) of HCV in the Caribbean and identify gaps in surveillance of the disease. The literature for the period 1 January 2005 to October 2022 was reviewed to gather country-specific data on HCV across the Caribbean. References were identified through indexed journals accessed through established databases using the following keywords: Caribbean, genotype distribution, and general epidemiologic characteristics. The usage pattern of HCV drugs was determined from information obtained from pharmacists across the Caribbean including Jamaica. The prevalence of HCV in the Caribbean was 1.5%; the region should therefore be considered an area of moderate HCV prevalence. The prevalence of HCV among intravenous drug users (21.9–58.8%), persons living with HIV/AIDS (0.8 to 58.5%), prisoners (32.8–64%), and men who have sex with men (MSM) (0.8–6.9%) was generally higher than in the general population (0.8–2.3%). Genotype 1 (83%) was most prevalent followed by genotypes 2 (7.2%) and 3 (2.1%), respectively. Less than 50% of countries in the Caribbean have reliable or well-curated surveillance data on HCV. Drugs currently being used for treatment of HCV infections across the Caribbean include Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir). Some of these drugs are only available in the private sector and are sourced externally whenever needed. While trends point to a potentially higher prevalence of HCV, it will require well-designed random surveys to obtain better estimates of the infection seroprevalence, supported by strong public health laboratory systems. DAAs that are pan-genotypic should translate into treatments that are affordable, accessible, and available to improve cure rates and reduce the HCV burden in the population.